BRIEF—Transpire Bio inks agreement with Recipharm

USA-based Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has entered into a definitive agreement with Sweden-headquartered contract development and manufacturing organization Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

TRB-1 and TRB-2, the first products developed by Transpire Bio will be indicated for the treatment of asthma and COPD, intended for advanced markets.

“Our mission is to improve access to important, life-saving inhaled therapies, and to introduce new inhaled therapies to help address areas of significant unmet medical need,” said Dr Xian-Ming Zeng, chief executive of Transpire Bio.

“TRB-1 and TRB-2 are our first offerings in development which will help improve access for potentially millions of patients. We are very excited to be working with Recipharm to advance these important medicines,” he added.